Premier Perspectives The blog for insider insights in clinical development Clinical Research: Phase 1 - Phase 4 5 Key Takeaways: Insights on Alternative Designs to the Traditional 3+3 Design in Phase 1 Dose Escalation Studies By Andreas Schreiner April 8, 2021 Featured Posts Consulting Parkinson’s: Why Has Disease Modification Failed — and What Now? By Andreas Schreiner December 19, 2018 Clinical ResearchPhase 1 - Phase 4 Finding the Path to Disease Modification in Parkinson’s Disease By Andreas Schreiner November 29, 2018 Recent Posts By expertise area All expertise areas AnalgesiaDermatologyMedical DeviceNeuroscienceOncology & HematologyPediatricsRare DiseaseOtherCOVID-19Cell & Gene TherapyWomen's HealthDiagnosticsReal-World & Late Phase By functional area All functional areas Clinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development New Research Highlights the Challenges of Studying Alzheimer’s Disease By Andreas Schreiner October 30, 2018 Clinical ResearchPhase 1 - Phase 4 Making the Case for Long-acting Antipsychotic Treatment By Andreas Schreiner September 11, 2018 × ALSO OF INTERESTGene Therapy 101: From the 1960s to TodayOutsourcing-Pharma – Trials suggest...Outsourcing-Pharma – Clinical trial logistics...
